Dr. Lu joined Tianjin University in November, 2020.  More than 40 papers have been published during past few years, including Journal of the National Cancer Institute (IF:13.506), Journal for Immunotherapy of Cancer (IF:13.751), Cancer Immunology Research (IF:11.151), Oncogene(IF:9.87), OncoImmunology (IF:8.11), Cancer Letters (IF:8.709), etc. There are totally 7 publications with IF over 10. An U.S. patent has been awarded. One NIH grant has been finished and two NSFC grants are active. H-Index is 26 based on Google Scholar.

 In last few years, immune checkpoint inhibitor (ICI) immunotherapy has made clinically significant breakthroughs in the treatment of human cancer. Science magazine named T cell-based cancer immunotherapy“Breakthrough of the year”in 2013. Since 2014, monoclonal antibodies that block programmed death-1 (PD-1) and programmed death-1 ligand-1 (PD-L1) have been approved for treatment of melanoma, non-small cell lung cancer, renal cell carcinoma and other human cancers. Currently, a long list of human cancers is being tested in clinical trials and has shown promising response to ICI immunotherapy. However, despite this breakthrough of ICI in many types of human cancers, pancreatic cancer and colorectal cancer stand out as two of the few human cancers that do not respond to ICI immunotherapy.The immunological and molecular mechanisms underlying pancreatic and colorectal cancer non-response to ICI immunotherapy are currently unknown and are the frontline of cancer research and therapy.  

Cancer is a disease of the tumor microenvironment which includes tumor cells, immune cells, and other types of cells. Tumor cells and immune cells are the two major types of cells in the tumor microenvironment. Immune cells respond as tumor development to mount an anti-tumor immune response to suppress the tumor. However, tumor cells can either secrete inhibitory mediators to suppress the T cell-mediated anti-tumor immune response or induce immune suppressive cells such as myeloid-derived suppressive cells (MDSCs) to suppress T cell function. Therefore, the dynamic interactions between tumor cells, T cells and immune suppressive cells (MDSCs) in the tumor microenvironment not only determine the outcome of cancer as a disease but perhaps also control cancer response to ICI immunotherapy. Therefore, cancer must be studied in the context of tumor microenvironment. Our research program include research topics that target tumor cells, T cells and MDSCs in the tumor microenvironment. The research interests are focused on the molecular mechanism underlying pancreatic cancer and colorectal cancer immune evasion, as well as the drug development to improve the efficacy of immunotherapy.     

      Grants

       2018   NIH   Development of ceramide analogs as enhancers for colon cancer immunotherapy    PI    Finished

       2019   NSFC   Function of tumor- and MDSC-expressed PD-L1 in pancreatic cancer immune evasion    PI    Finished     

       2021   TJU Grant  Molecular mechanism of pancreatic and colorectal cancer immune evasion and immunotherapy development   PI   Active    

       2022   NSFC    SUV39H1-H3K9me3 epigenetic axis regulates colorectal cancer immune evasion    PI    Active